Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
ADMA BIOLOGICS, INC. (ADMA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/18/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., Aug 9, 2023"
07/19/2023 8-K Quarterly results
06/06/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2023 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its first quarter 2023 financial results and provided a business update."
05/02/2023 8-K Credit agreement amendment
Docs: "Form of Warrant to Purchase Common Stock",
"Amendment No. 2 to the Credit and Guaranty Agreement",
"ADMA and our willingness to amend the previously underwritten terms speak to the above-expectation commercial execution.”"
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., March 23, 2023 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2022 financial results and provided a business update."
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 5.4% stake in ADMA Biologics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "RAMSEY, N.J., BOCA RATON, Fla. and Hammond, LA. – February 8, 2023 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana. This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022. With the FDA approval announced today, this facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. “The successful expansion of ADMA’s plasma collection network supports the Company’s goal of plas..."
02/03/2023 SC 13G BlackRock Inc. reports a 6.9% stake in ADMA BIOLOGICS INC
01/17/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., January 17, 2023 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million, an increase of approximately 89% over the fourth quarter of 2021, and full year 2022 preliminary, unaudited revenue of approximately $153-$154 million, an increase of approximately 90% over full year 2021."
12/09/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/09/2022 8-K Quarterly results
12/07/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/07/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
12/06/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy